Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.
Navaira Shoaib, MBBS
Advertisement
Articles by Navaira Shoaib, MBBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
The Evolving Role of Subcutaneous Therapies in EGFR+ NSCLC
5
